Hydroxyl-modified magnetite nanoparticles as novel carrier for delivery of methotrexate

Farjadian, Fatemeh; Ghasemi, Soheila; Mohammadi-Samani, Soliman

doi:10.1016/j.ijpharm.2016.03.022

Cited by 50 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today magnetic-based NP have vast arrays of application in drug and gene delivery [287,288] and diagnosis [289]. Feridex was a commercial product of iron oxide based NPs used as a contrast agent for MRI.…”

Section: Metal-based Nanopharmaceuticalsmentioning

confidence: 99%

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Farjadian

Ghasemi

Gohari

et al. 2018

Nanomedicine (Lond.)

Self Cite

448

213

View full text Add to dashboard Cite

There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.

show abstract

Section: Metal-based Nanopharmaceuticalsmentioning

confidence: 99%

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Farjadian

Ghasemi

Gohari

et al. 2018

Nanomedicine (Lond.)

Self Cite

448

213

View full text Add to dashboard Cite

show abstract

“…FR is a surface biomarker overexpression on tumor cell membrane (Khan et al, 2012 ). Many targeted approaches for MTX have been exploited to reduce adverse effects, improve bioavailability and maximize treatment effect (Jain et al, 2015 ; Farjadian et al, 2016 ; Guo et al, 2018 ; Liu et al, 2017 ). Earlier paper demonstrated that MTX-mediated nanoparticle drug delivery system would be a predominant targeted anticancer chemotherapeutic formulation (Chen et al, 2014 ; Li et al, 2017a , 2017b ; Singh & Subudhi, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

et al. 2018

View full text Add to dashboard Cite

Combination chemotherapy is widely exploited for suppressing drug resistance and achieving synergistic anticancer efficacy in the clinic. In this paper, the nanostructured targeting methotrexate (MTX) plus pemetrexed (PMX) chitosan nanoparticles (CNPs) were developed by modifying methoxy polye (thylene glycol) (mPEG), in which PEGylation CNPs was used as stealth nanocarriers (PCNPs) and MTX was employed as a targeting ligand and chemotherapeutic agent as well. Studies were undertaken on human lung adenocarcinoma epithelial (A549) and Lewis lung carcinoma (LLC) cell lines, revealing the anti-tumor efficacy of nanoparticle drug delivery system. The co-delivery nanoparticles (MTX-PMX-PCNPs) had well-dispersed with sustained release behavior. Cell counting kit-8 (CCK8) has been used to measure A549 cell viability and the research showed that MTX-PMX-PCNPs were much more effective than free drugs when it came to the inhibition of growth and proliferation. Cell cycle assay by flow cytometry manifested that the MTX-PMX-PCNPs exhibited stronger intracellular taken up ability than free drugs at the same concentration. In vivo anticancer effect results indicated that MTX-PMX-PCNPs exhibited a significantly prolong blood circulation, more tumoral location accumulation, and resulted in a robust synergistic anticancer efficacy in lung cancer in mice. The results clearly demonstrated that such unique synergistic anticancer efficacy of co-delivery of MTX and PMX via stealth nanocarriers, providing a prospective strategy for lung cancer treatment.

show abstract

“…To investigate cytotoxic effects, MTT assay was used according to the reported procedure 35. First, the MCF-7 cells were cultured in RPMI 1640-supplemented medium with 10% FBS at 37°C (5% CO 2 ) incubator.…”

Section: Methodsmentioning

confidence: 99%

<p>Temperature and pH-responsive nano-hydrogel drug delivery system based on lysine-modified poly (vinylcaprolactam)</p>

Farjadian¹,

Rezaeifard²,

Naeimi³

et al. 2019

IJN

Self Cite

View full text Add to dashboard Cite

Background Smart materials capable of responding to external stimuli are noteworthy candidates in designing drug delivery systems. In many of the recent research, temperature and pH have been recognized as the main stimulating factors in designing systems for anti-cancer drugs delivery systems. Purpose In this study, thermo and pH-responsive character of a nano-carrier drug delivery platform based on lysine modified poly (vinylcaprolactam) hydrogel conjugated with doxorubicin was assessed. Methods Poly (vinylcaprolactam) cross-linked with poly (ethyleneglycol) diacrylate was prepared via RAFT polymerization, and the prepared structure was linked with lysine through ring-opening. The anti-cancer drug doxorubicin, was linked to lysine moiety of the prepared structure via Schiff-base reaction. The prepared platform was characterized by 1 HNMR and FT-IR, while molecular weight characterization was performed by size exclusion chromatography. The temperature-responsive activity was evaluated using differential scanning calorimetry and dynamic light scattering. In vitro release pattern in simulated physiologic pH at 37°C was compared with acidic pH attributed to tumor site and elevated temperature. The anticancer efficiency of the drug-conjugated structure was evaluated in breast cancer cell line MCF-7 in 24 and 48 h, and cell uptake assay was performed on the same cell line. Conclusion According to the results, well-structure defined smart pH and temperature responsive nano-hydrogel was prepared. The enhanced release rates are observed at acidic pH and elevated temperature. We have concluded that the doxorubicin-conjugated nanoparticle results in higher cellular uptakes and more cytotoxicity.

show abstract

Hydroxyl-modified magnetite nanoparticles as novel carrier for delivery of methotrexate

Cited by 50 publications

References 29 publications

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

<p>Temperature and pH-responsive nano-hydrogel drug delivery system based on lysine-modified poly (vinylcaprolactam)</p>

Contact Info

Product

Resources

About